Takeda plans to launch its dengue vaccine, Qdenga, in India by next year, partnering with Biological E to support the 'Make-in-India' initiative. The company will employ a tiered pricing model to enhance accessibility and is currently undergoing regulatory processes, with expectations of licensing in 2026.Original Article